Imunon Appoints New Interim CFO from Consulting Firm with Significant Hourly Rate
IMNN is trading near its 52-week low of $1.7 (4.7% above the low).
Summary
Imunon announced the retirement of its interim CFO and the appointment of a new interim CFO from a consulting firm, with an hourly rate of $475 for an estimated 40-60 hours per month.
Key Events · Executive and Board Changes · IMNN
-
Interim CFO Retirement
Jeffrey Church, the interim Chief Financial Officer, will retire effective July 1, 2026. His departure is due to retirement and without any disagreements with management. He will continue in a consulting role for a monthly retainer of $10,000.
-
New Interim CFO Appointed
Josh Blacher has been appointed as the new interim Chief Financial Officer, effective July 1, 2026. Mr. Blacher will serve through a master services agreement with Danforth Health, Inc., a financial advisory services firm.
-
Significant Consulting Cost
The company will pay Danforth Health $475 per hour for Mr. Blacher's services, with an anticipated commitment of 40 to 60 hours per month. This translates to an annual cost of approximately $228,000 to $342,000.
-
Experienced Financial Leadership
Mr. Blacher has extensive experience serving as a CFO for various life sciences companies in a consulting capacity, including BullFrog AI Holdings, Inmed Pharmaceuticals, Therapix Biosciences, and Galmed Pharmaceuticals.
Analysis · IMNN · Life Sciences
Imunon, a micro-cap company facing a going concern warning, has appointed a new interim Chief Financial Officer through a consulting agreement. While the new CFO brings relevant experience, the arrangement entails a substantial annual cost of $228,000 to $342,000. This represents a significant operational expense for a company with limited cash, potentially impacting its cash runway despite recent financing efforts.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNN was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $1.70 to $11.19. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.